Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2012
12/20/2012CA2838079A1 Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
12/20/2012CA2838051A1 Process for the preparation of a chiral compound
12/20/2012CA2837926A1 Scyllo - inositol for the treatment of behavioral and psychiatric disorders
12/20/2012CA2837268A1 Compositions and methods for modulating a kinase
12/20/2012CA2837248A1 Novel phthalazinone -pyrrolopyrimidinecarboxamide derivatives
12/20/2012CA2836856A1 Treatment of respiratory disorders using trpa1 antagonists
12/20/2012CA2836804A1 Pyrazole derivatives useful as aldosterone synthase inhibitors
12/20/2012CA2836485A1 Bicyclo (3.1.0) hexane- 2 , 6 -dicarboxylic acid derivatives as mglu2 receptor agonist
12/20/2012CA2833169A1 Antimicrobial compounds and methods of making and using the same
12/20/2012CA2824870A1 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
12/20/2012CA2818907A1 Hybrid molecules containing pharmacophores of fluconazole as antifungal agents and their preparation
12/19/2012EP2535716A2 Cancer marker and therapeutic target
12/19/2012EP2535413A2 Splice switching oligomers for the TNF superfamily receptors and their use in treatment of disease
12/19/2012EP2535412A1 New treatment for muscular dystrophies
12/19/2012EP2535410A1 Aptamer to fgf2 and use thereof
12/19/2012EP2535345A1 Anticancer nucleoside analogs
12/19/2012EP2535342A1 Salt of fused heterocyclic derivative and crystal thereof
12/19/2012EP2535339A1 Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
12/19/2012EP2535338A1 Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile
12/19/2012EP2535337A1 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form
12/19/2012EP2535336A1 Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
12/19/2012EP2535335A1 Use of yessotoxin and analogues and derivatives thereof for treating and/or preventing neurodegenerative diseases linked to tau and beta amyloid
12/19/2012EP2535332A1 Sinomenine derivatives, synthetic methods and uses thereof
12/19/2012EP2535330A2 Iminopyridine derivative and use thereof
12/19/2012EP2535329A2 Spiro-piperidine derivatives
12/19/2012EP2535059A1 Use of compound binding to msin3b that specifically binds to neuron restrictive silencer factor (nrsf)
12/19/2012EP2535051A1 Read through inducer, and therapeutic agent for nonsense-mutation-type genetic diseases
12/19/2012EP2535050A2 Compositions and methods for detection of lysosomal storage disease
12/19/2012EP2535049A1 Tadalafil for the treatment of dementia
12/19/2012EP2535048A1 Extended release preparation
12/19/2012EP2535047A1 Nutritional composition, food supplement comprising said nutritional composition and kit comprising said food supplement
12/19/2012EP2535046A1 Use of mecamylamine in the treatment of pathogen-infected patients with central nervous system disorder
12/19/2012EP2535045A1 Pharmaceutical composition of lansoprazole
12/19/2012EP2535044A1 Enterically coated cysteamine, cystamine and derivatives thereof
12/19/2012EP2534167A2 Progesterone receptor antagonists
12/19/2012EP2534166A2 Progesterone receptor antagonists
12/19/2012EP2534158A1 Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity
12/19/2012EP2534157A1 Prasugrel in micronized, crystalline form and pharmaceutical composition thereof
12/19/2012EP2534156A1 7-aminofuropyridine derivatives
12/19/2012EP2534155A1 Compounds for treating respiratory syncytial virus infections
12/19/2012EP2534153A1 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
12/19/2012EP2534151A1 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
12/19/2012EP2534150A2 Methods of treating viral infection
12/19/2012EP2534149A1 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
12/19/2012EP2534148A1 Purine derivatives and their pharmaceutical uses
12/19/2012EP2534145A2 Therapeutic methods and compositions involving allosteric kinase inhibition
12/19/2012EP2534144A1 Preparation process of the sodium salt of esomeprazole
12/19/2012EP2534139A1 Novel aminoalkyl-oxazole and aminoalkyl-thiazole carboxylic acid amides as regeneration-promoting substances for sensory organs and post-mitotic tissue
12/19/2012EP2534138A1 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors
12/19/2012EP2534137A1 Pyridazine derivatives useful as cannabinoid - 2 agonists
12/19/2012EP2534135A2 Novel forms of ivabradine hydrochloride
12/19/2012EP2534132A1 Substituted pyrrolidine-2-carboxamides
12/19/2012EP2534131A1 Methods of synthesizing and isolating n-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
12/19/2012EP2533828A1 Removal of virulence factors through extracorporeal therapy
12/19/2012EP2533802A2 Methods of reducing or inhibiting toxic effects associated with a bacterial infection using alkaline phosphatase
12/19/2012EP2533799A2 Methods for the use of progestogen as a glucocorticoid sensitizer
12/19/2012EP2533798A2 P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
12/19/2012EP2533789A1 Methods for improving sperm functionality
12/19/2012EP2533787A1 Use of isorhamnetin triglycosides
12/19/2012EP2533786A2 Methods and compositions to improve mechanical resistance of teeth
12/19/2012EP2533785A1 Treatment of loss of sense of touch with saxitoxin derivatives
12/19/2012EP2533784A1 Sanglifehrin based compounds
12/19/2012EP2533783A1 Compounds and methods
12/19/2012EP2533782A1 PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS
12/19/2012EP2533781A2 Method for treating hematological cancers
12/19/2012EP2533780A1 5-ht4 receptor agonists for the treatment of dementia
12/19/2012EP2533779A2 Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
12/19/2012EP2533778A1 Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
12/19/2012EP2533777A1 Pharmaceutical compositions comprising fluticasone, tiotropium and sodium cromoglycate
12/19/2012EP2533776A1 A dermatological composition comprising a combination of adapalene and benzoyl peroxide for the treatment of acne in non- caucasian population with decrease of post- inflammatory hyperpigmentation
12/19/2012EP2533775A1 Carbonic anhydrase inhibitors
12/19/2012EP2533774A2 Use of agomelatine for the preparation of drugs for treating obsessive compulsive disorder (ocd)
12/19/2012EP2533767A1 Pharmaceutical compositions comprising a combination of metformin and sitagliptin
12/19/2012EP2533766A2 Pharmaceutical mini-tablets for sustained release of flecainide acetate
12/19/2012EP2533765A2 Pharmaceutical compositions comprising formoterol and mometasone
12/19/2012EP2533760A1 Liquid composition comprising a non-menthol cooling agent and a thickener for treating a respiratory symptom
12/19/2012EP2533759A2 Magnetically sensitive drug carriers for treatment or targeted delivery
12/19/2012EP2533754A2 Compositions and methods for reducing appearance of under-eye dark circles
12/19/2012EP2533653A1 Homoarginine as a biomarker for the risk of mortality
12/19/2012EP2533652A1 Nutritional compositions
12/19/2012EP2533645A1 Methods and compositions for improving cognitive function
12/19/2012EP2533643A1 Derivatives of betulin
12/19/2012EP2533642A1 BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
12/19/2012EP2533641A2 Hydrazine-substituted anthranilic acid derivatives
12/19/2012EP2533639A1 Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
12/19/2012EP2533638A1 Novel s-nitrosoglutathione reductase inhibitors
12/19/2012EP2533637A1 Chromone inhibitors of s-nitrosoglutathione reductase
12/19/2012EP2533635A1 Compositions and methods for treating obesity and obesity-related conditions
12/19/2012EP2533634A1 Neuroprotection in demyelinating diseases
12/19/2012EP2268652B1 Platinum-n-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof
12/19/2012CN1926103B Sulphonylpyrroles as HDAC inhibitors
12/19/2012CN1823071B Thienopyrimidine derivatives as potassium channel inhibitors
12/19/2012CN102834513A Antiviral therapeutic agents
12/19/2012CN102834512A Metal salen complex derivative and process for production thereof
12/19/2012CN102834406A Novel [3.2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
12/19/2012CN102834405A Progesterone receptor antagonists
12/19/2012CN102834401A Fatty acid amide hydrolase inhibitors
12/19/2012CN102834400A 2,5-substituted oxazolopyrimidine derivatives
12/19/2012CN102834399A Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
12/19/2012CN102834396A Aryl - /heteroaryl - cyclohexenyl - tetraazabenzo [e] azulenes as vasopressin antagonists
1 ... 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 ... 7860